Retinopathy during the first 5 years of type 1 diabetes and subsequent risk of advanced retinopathy
Malone JI, Gao X, Lorenzi GM, et al.
Diabetes Care. dc221711.
Leggi
Breaking news
A Comparison of CGM estimated hemoglobin A1c in adults with type 1 or type 2 diabetes
Salam M, Bailey R, Calhoun P, et al.
Diabetes Technol Ther. Pub. online 6 Dec 2022.
Leggi
Improved glycemia with Hybrid Closed-Loop (HCL) versus Continuous Subcutaneous Insulin Infusion (CSII) therapy: results from a randomized controlled trial
Garg SK, Grunberger G, Weinstock RS, et al.
Diabetes Technol Ther. Pub. online 6 Dec 2022.
Leggi
Associations between diabetic retinopathy, mortality, disease, and mental health: an umbrella review of observational meta-analyses
Trott M, Driscoll R, Pardhan S
BMC Endocr Disord. 2022;22(1):311.
Leggi
Impact of expanding access to continuous glucose monitoring systems among insulin users with type 1 or type 2 diabetes
Pathak S, Kearin K, Kahkoska A et al.
Diabetes Technol Ther. Pub. online 8 Dec 2022.
Leggi
Continuous glucose monitoring and metrics for clinical trials: an international consensus statement
Battelino T, Alexander CM, Amiel SA, et al.
The Lancet Diabetes and Endocrinology. Pub. online, 6 December 2022.
Leggi
Serum neurofilament light chain: a novel biomarker for early diabetic sensorimotor polyneuropathy
Maalmi H, Strom A, Petrera A, et al.
Diabetologia. Pub. online 6 Dec 2022.
Leggi
Initiation of sodium-glucose cotransporter-2 inhibitors at lower HbA1c threshold attenuates eGFR decline in type 2 diabetes patients with and without cardiorenal disease: A propensity-matched cohort study
Cheung JTK, Yang A, Wu H, et al.
Diabetes Res Clin Pract. Pub. online 6 Dec 2022.
Leggi
Two decades of diabetes prevention efforts: a call to innovate and revitalize our approach to lifestyle change
Golovaty I, Ritchie ND, Tuomilehto J, et al.
Diabetes Res Clin Pract. 2022;110195.
Leggi
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
Urva S, Coskun T, Loh MT, et al.
Lancet. 2022;400(10366):1869-1881.
Leggi